Why Is a Fever an Emergency During DLBCL Treatment?
At a Glance
During DLBCL chemotherapy, a fever of 100.4°F (38°C) or higher may be the first sign of an infection when neutrophils are low. Call your oncology team immediately, follow their threshold, and do not mask the fever with medication.
In this answer
5 sections
During DLBCL treatment regimens like R-CHOP, chemotherapy suppresses your bone marrow, temporarily lowering your white blood cell count [1][2]. Because these cells are essential for fighting off bacteria and fungi, an infection can escalate much faster than it would in a healthy person [3]. A fever is often the earliest—and sometimes the only—warning sign [1]. That is why a temperature of 100.4°F (38°C) is treated as a medical emergency requiring prompt assessment and, if an infection is suspected, rapid treatment with antibiotics that cover many likely bacteria [2][4].
What To Do Now: Action Steps
If you currently have a fever of 100.4°F (38°C) or higher, or feel suddenly unwell:
- Check your temperature using the method approved by your oncology team. (Avoid rectal thermometers, which can cause internal injury and introduce infection).
- Call your 24-hour oncology hotline immediately. Tell them you are receiving chemotherapy for DLBCL and may be neutropenic. Follow their specific emergency pathway.
- Do not take acetaminophen, ibuprofen, or aspirin to lower the fever before calling, as this can hide symptoms or cause bleeding complications [5][6]. If you already took one, call anyway and report what you took and when.
- Do not drive yourself if you feel dizzy or faint.
- Call emergency services (911) if you have trouble breathing, chest pain, new confusion, severe weakness, blue/gray lips, or cannot keep fluids down.
What is Febrile Neutropenia?
Chemotherapy reduces your levels of neutrophils, the specific white blood cells that act as your primary defense against infection [1]. When your neutrophil count drops below a safe threshold, you have neutropenia. When you develop a fever alongside this low count, the condition is called febrile neutropenia [2].
Normally, an infection causes swelling, redness, pain, or pus. However, because a neutropenic body has a blunted inflammatory response, these classic signs may not appear [7][8]. A fever might be your only clue that an infection is present [1][2]. Importantly, a serious infection can sometimes happen without a fever. Severe chills, a new cough, burning during urination, or redness around a central line port should also prompt an immediate call to your care team [7][1].
The Risk of Sepsis
Without enough neutrophils, bacterial or fungal infections—even from bacteria naturally found on your skin or in your gut—can be harder to control [9][10]. If not treated promptly, this can lead to sepsis [3]. Sepsis is a life-threatening, dysregulated body-wide response to an infection that can cause organ dysfunction and a dangerous drop in blood pressure, known as septic shock [3].
Because clinical deterioration can occur rapidly, sometimes before other obvious signs of infection appear, immediate medical evaluation is critical [11][12]. This urgency is a precaution: prompt medical care is the best way to prevent severe complications, and seeking help quickly does not mean you already have sepsis.
The 100.4°F (38°C) Rule
In medical guidelines, a neutropenic fever is formally defined as a single oral temperature of 101.0°F (38.3°C), or a temperature of 100.4°F (38.0°C) sustained for one hour [2][13].
However, your oncology team’s safety threshold is likely lower and more immediate. If they instruct you to call at the first reading of 100.4°F (38.0°C), you must follow their guidance [14]. Do not wait for your temperature to rise further, and do not wait an hour to see if it stays high [14][1].
When you are evaluated at the clinic or hospital, clinicians will check your vital signs, draw blood for a complete blood count (CBC) and blood cultures, and check for infection sources [2]. If appropriate, they will start broad-spectrum antibiotics—ideally within one hour of your arrival [2][15]. While intravenous (IV) antibiotics in the hospital are common, some carefully selected, low-risk patients may be managed safely with outpatient oral antibiotics based on their medical team’s assessment [16][17].
Why You Should Not Self-Medicate a Fever
You should not take fever-reducing medications for a new fever unless your oncology team explicitly tells you to do so [5][18].
- Acetaminophen (Tylenol) can artificially lower your temperature, masking the fever and delaying the urgent medical assessment you need [5][18].
- Ibuprofen, aspirin, and other NSAIDs carry additional risks. Chemotherapy can lower your platelets (the cells that help blood clot) and make your kidneys vulnerable [6][19]. NSAIDs can increase the risk of serious bleeding and kidney damage [6].
Never use fever reducers as a substitute for urgent medical care. A fever during chemotherapy is a time-critical warning where rapid professional assessment saves lives.
Common questions in this guide
Why can a fever become dangerous during DLBCL chemotherapy?
What temperature should prompt a call during DLBCL treatment?
What should I do if I develop a fever after chemotherapy for DLBCL?
Can a serious infection happen without a fever when neutrophils are low?
Why should I avoid Tylenol or ibuprofen before calling about a chemotherapy fever?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is the specific phone number I should call if I develop a fever after hours or on the weekend?
- 2.Which emergency room or urgent care center should I go to, and how should I inform them upon arrival that I am a chemotherapy patient?
- 3.What specific thermometer type and measurement method do you recommend I use to monitor my temperature accurately at home?
- 4.When is my risk for neutropenia usually the highest after each R-CHOP chemotherapy cycle?
- 5.Will I be receiving growth factor injections (like pegfilgrastim) to help my white blood cell counts recover, and how does that affect my fever risk?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (19)
- 1
Oncologic Emergencies: The Fever With Too Few Neutrophils.
Long B, Koyfman A
The Journal of emergency medicine 2019; (57(5)):689-700 doi:10.1016/j.jemermed.2019.08.009.
PMID: 31635928 - 2
Management of Neutropenic Fever in Persons with Cancer.
Doyle-Lindrud S
The Nursing clinics of North America 2025; (60(3)):479-489 doi:10.1016/j.cnur.2024.09.004.
PMID: 40716808 - 3
Soluble CD14 as a Diagnostic and Prognostic Biomarker in Hematological Patients with Febrile Neutropenia.
Korpelainen S, Intke C, Hämäläinen S, et al.
Disease markers 2017; (2017()):9805609 doi:10.1155/2017/9805609.
PMID: 28845081 - 4
Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.
Pherwani N, Ghayad JM, Holle LM, Karpiuk EL
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2015; (72(8)):619-31 doi:10.2146/ajhp140194.
PMID: 25825185 - 5
Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.
Taplitz RA, Kennedy EB, Bow EJ, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(14)):1443-1453 doi:10.1200/JCO.2017.77.6211.
PMID: 29461916 - 6
Assessment of factors affecting timing of discharge in pediatric cancer patients with febrile neutropenia.
Üstün C, Aydın B, Kurucu N, et al.
The Turkish journal of pediatrics 2025; (67(6)):841-854 doi:10.24953/turkjpediatr.2025.5170.
PMID: 41636196 - 7
[Neutropenia - when is GCSF support indicated?]
Rehlinghaus M, Rehker P, Che Y, et al.
Aktuelle Urologie 2024; (55(1)):38-43 doi:10.1055/a-2128-4965.
PMID: 37607583 - 8
Outcome of severe infections in afebrile neutropenic cancer patients.
Strojnik K, Mahkovic-Hergouth K, Novakovic BJ, Seruga B
Radiology and oncology 2016; (50(4)):442-448 doi:10.1515/raon-2016-0011.
PMID: 27904453 - 9
Febrile neutropenia in the Middle East and North Africa Region: trends, management, and outcomes (2000-2024)-A systematic review.
El Assaad N, Azzi A, Haddad F, et al.
IJID regions 2025; (16()):100682 doi:10.1016/j.ijregi.2025.100682.
PMID: 40703205 - 10
Patterns of Bacterial Isolates and their Resistance to Antibiotics in Patients with Chemotherapy-induced Febrile Neutropenia at a University Hospital.
Al Saifi SA, Al Adawi B, Burney I
Oman medical journal 2021; (36(4)):e290 doi:10.5001/omj.2021.87.
PMID: 34497720 - 11
Serum caspase-cleaved cytokeratin-18 fragment as a prognostic biomarker in hematological patients with febrile neutropenia.
Intke C, Korpelainen S, Lappalainen M, et al.
Clinical and experimental medicine 2022; (22(1)):83-93 doi:10.1007/s10238-021-00734-8.
PMID: 34255216 - 12
Novel biomarkers to identify complicated course of febrile neutropenia in hematological patients receiving intensive chemotherapy.
Jantunen E, Hämäläinen S, Pulkki K, Juutilainen A
European journal of haematology 2024; (113(4)):392-399 doi:10.1111/ejh.14264.
PMID: 38961525 - 13
Antibiotic stewardship in suspected neutropenic fever (ASTERIC trial): a multicentre, type 1 hybrid effectiveness-implementation, stepped-wedge, randomised controlled trial study protocol.
Rainer TH, Lam RPK, Tsang TC, et al.
BMJ open 2025; (15(11)):e108010 doi:10.1136/bmjopen-2025-108010.
PMID: 41290295 - 14
CE: Febrile Neutropenia in the Chemotherapy Patient.
Foley AM, Hoffman M
The American journal of nursing 2023; (123(5)):36-42 doi:10.1097/01.NAJ.0000931888.96896.a1.
PMID: 37021970 - 15
Consensus guidelines for ambulatory care for neutropenic fever.
Teh JSK, Singh N, Lambros B, et al.
Internal medicine journal 2025; (55 Suppl 7()):95-114 doi:10.1111/imj.70251.
PMID: 41521418 - 16
A cohort study on protocol-based nurse-led out-patient management of post-chemotherapy low-risk febrile neutropenia.
Ying FLM, Ping MCY, Tong M, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2018; (26(9)):3039-3045 doi:10.1007/s00520-018-4157-6.
PMID: 29556814 - 17
The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer.
de la Court JR, Bruns AHW, Roukens AHE, et al.
Infectious diseases and therapy 2022; (11(6)):2063-2098 doi:10.1007/s40121-022-00700-1.
PMID: 36229765 - 18
Implementation of a Protocol for Management of Febrile Neutropenia in the Emergency Department at Veteran Health Indiana.
Melikian L, Bullington S, Harris B, et al.
Federal practitioner : for the health care professionals of the VA, DoD, and PHS 2023; (40(Suppl 3)):S42-S45 doi:10.12788/fp.0371.
PMID: 38021097 - 19
Neutropenic sepsis is associated with distinct clinical and biological characteristics: a cohort study of severe sepsis.
Reilly JP, Anderson BJ, Hudock KM, et al.
Critical care (London, England) 2016; (20(1)):222 doi:10.1186/s13054-016-1398-y.
PMID: 27431667
This page is for informational purposes only and does not constitute medical advice. It explains why fever during DLBCL chemotherapy needs urgent assessment; follow your oncology team's instructions and contact them immediately about a fever or sudden illness.
Get notified when new evidence is published on Diffuse large B-cell lymphoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.